Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ: ACAD )

14.69 +0.07 (+0.48%)
Streaming Delayed Price Updated: 12:50 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
FDA Asks For Additional Study For Acadia's Pimavanserin In Alzheimer's-Associated Delusions
Via Benzinga
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
From Acadia Pharmaceuticals Inc.
Via Business Wire
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Why Is Acadia Pharmaceuticals (ACAD) Stock Down 33% Today?
Today, investors in Acadia Pharmaceuticals and ACAD stock are in selling mode. The FDA gave a thumbs down on a key drug. 
Via InvestorPlace
Why Acadia Pharma Shares Are Plunging Today
Via Benzinga
Why ACADIA Pharmaceuticals Shares Are Trading Higher Today?
Via Benzinga
Biotech Investors: August's Key PDUFA Catalysts You Must Know
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the... 
Via Benzinga
Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022
From Acadia Pharmaceuticals Inc.
Via Business Wire
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap of Monday's Biotech Catalysts - End of the Day Summary
Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least... 
Via Benzinga
Acadia Seeks FDA Approval For Genetic Neurological Disorder Candidate
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for trofinetide for the treatment of Rett syndrome. 
Via Benzinga
Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome
From Acadia Pharmaceuticals Inc.
Via Business Wire
Where ACADIA Pharmaceuticals Stands With Analysts
Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) within the last quarter: 
Via Benzinga
Analysts Try To See Beyond Acadia's Alzheimer's Disease Psychosis
HC Wainwright says that a negative AdCom vote on Acadia Pharmaceuticals Inc&# 
Via Benzinga
67 Biggest Movers From Yesterday
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.4% to close at $10.30 as the company agreed to be taken private by TPG Capital. 
Via Benzinga
Nasdaq Rises 2.5%; ACADIA Pharmaceuticals Shares Plummet
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 2.5% on Tuesday. 
Via Benzinga
Dow Jumps 550 Points; Convey Health Solutions Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 550 points on Tuesday. 
Via Benzinga
45 Stocks Moving In Tuesday's Mid-Day Session
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.8% to $10.31 as the company agreed to be taken private by TPG Capital,. 
Via Benzinga
U.S. Markets Open Higher; Lennar Earnings Top Views
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 500 points on Tuesday. 
Via Benzinga
Acadia Pharmaceuticals Crashes After FDA Panel Votes Down Its Alzheimer's Psychosis Drug
It's not looking good for Nuplazid in Alzheimer's disease psychosis. 
Via Investor's Business Daily
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Goldman Sachs cut SunPower Corporation. (NASDAQ: SPWR) price target from $19 to $13. SunPower shares fell 3.1% to $17.37 in pre-market trading. 
Via Benzinga
Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis
From Acadia Pharmaceuticals Inc.
Via Business Wire
The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Acadia Pharmaceuticals Stock Trading Halted Today
From Acadia Pharmaceuticals Inc.
Via Business Wire
HC Wainwright Sees Opportunity For Acadia's Alzheimer's Candidate
HC Wainwright says FDA's briefing document on ACADIA Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin was not unexpected. 
Via Benzinga
Why Acadia Pharma Surged Despite A Negative FDA Take On Its Lead Drug
There were no surprises in the FDA's assessment of an Alzheimer's drug from Acadia Pharmaceuticals, and ACAD stock surged Wednesday. 
Via Investor's Business Daily
5 Biotech Stocks To Watch During The Week Of June 13
Biotech stocks continued to be under pressure in the past week amid broader market weakness, precipitated by economic worries. Company-specific developments also triggered downward moves. Here's a... 
Via Benzinga
71 Biggest Movers From Yesterday
Gainers Sidus Space, Inc. (NASDAQ: SIDU) shares jumped 225% to close at $4.68 on Wednesday after the company announced it is part of Collins Aerospace team which was awarded NASA's Exploration... 
Via Benzinga
55 Stocks Moving In Wednesday's Mid-Day Session
Gainers Sidus Space, Inc. (NASDAQ: SIDU) shares surged 92.4% to $2.77 after the company announced it is part of Collins Aerospace team which was awarded NASA's Exploration Extravehicular Activity... 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.